Granisetron transdermal - Abeille Pharmaceuticals

Drug Profile

Granisetron transdermal - Abeille Pharmaceuticals

Alternative Names: AB-1001; Granisetron transdermal - Abeille; Inno-P08002; SyB D-0701; SyB-0701

Latest Information Update: 27 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abeille Pharmaceuticals
  • Developer Abeille Pharmaceuticals; INNOPHARMAX; SymBio Pharmaceuticals
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chemotherapy-induced nausea and vomiting
  • Phase II Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 01 Jun 2015 Phase III development is ongoing
  • 28 Jan 2013 SymBio completes a phase III trial in Radiotherapy induced nausea and vomiting in Japan (NCT01700140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top